联邦制药(03933)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03933 联邦制药

休市中 10-23 16:08:09

6.830

-0.070

-1.01%

最高6.880	最低6.670	成交量526.40万
今开6.830	昨收6.900	日振幅3.04%
总市值134.55亿	流通市值134.55亿	总股本19.70亿
成交额3,573万	换手率0.27%	流通股本19.70亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03933","market":"HK","secType":"STK","nameCN":"联邦制药","latestPrice":6.83,"timestamp":1792742889006,"preClose":6.9,"halted":0,"volume":5264000,"delay":0,"changeRate":-0.010144927536231925,"floatShares":1970000000,"shares":1970000000,"eps":1.3011547254005473,"marketStatus":"休市中","change":-0.07,"latestTime":"10-23 16:08:09","open":6.83,"high":6.88,"low":6.67,"amount":35726910,"amplitude":0.030435,"askPrice":6.85,"askSize":40000,"bidPrice":6.83,"bidSize":32000,"shortable":3,"etf":0,"ttmEps":0.3229956386799777,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1792978200000},"marketStatusCode":7,"adr":0,"listingDate":1181836800000,"exchange":"SEHK","adjPreClose":6.9,"dividendRate":0.043763,"openAndCloseTimeList":[[1792719000000,1792728000000],[1792731600000,1792742400000]],"volumeRatio":0.8951065693748401,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03933","defaultTab":"news","newsList":[{"id":"2677958931","title":"瑞银：降联邦制药(03933.HK)评级至“中性” 重申先声药业(02096.HK)为首选","url":"https://stock-news.laohu8.com/highlight/detail?id=2677958931","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677958931?lang=zh_cn&edition=full","pubTime":"2026-10-22 16:41","pubTimestamp":1792658506,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","02096","03933","IE00B3M56506.USD","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674823607","title":"东吴证券：维持联邦制药(03933)“买入”评级 主业筑底回升","url":"https://stock-news.laohu8.com/highlight/detail?id=2674823607","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674823607?lang=zh_cn&edition=full","pubTime":"2026-10-12 11:12","pubTimestamp":1791774772,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东吴证券发布研报称，考虑到联邦制药为青霉素类抗生素产业链垂直一体化企业，中间体、原料药与兽药动保环节具备规模与成本优势，并已通过胰岛素类似物及UBT251等管线进入内分泌/代谢领域，该行看好公司未来主业周期修复与创新价值兑现形成共振，维持“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1505726.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03933","601555"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674823602","title":"东吴证券：维持联邦制药(03933.HK)“买入”评级 主业筑底回升","url":"https://stock-news.laohu8.com/highlight/detail?id=2674823602","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674823602?lang=zh_cn&edition=full","pubTime":"2026-10-12 11:12","pubTimestamp":1791774772,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B3M56506.USD","03933","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157945476","title":"联邦制药9月无新增股份发行或回购","url":"https://stock-news.laohu8.com/highlight/detail?id=1157945476","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157945476?lang=zh_cn&edition=full","pubTime":"2026-10-05 10:41","pubTimestamp":1791168065,"startTime":"0","endTime":"0","summary":"联邦制药国际控股有限公司于2026年10月5日发布了截至2026年9月30日的证券变动月报表。根据公告，联邦制药普通股于当月未发生新增发行、购回或注销，报告期末已发行股份数为1,970,276,508股，库藏股为0股，合计已发行股份总数1,970,276,508股，与上月底持平。联邦制药确认已满足联交所规定的公共持股量要求，并持续遵守香港联交所《上市规则》及适用法律法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671576276","title":"港股异动 | 联邦制药(03933)涨超3% 德谷胰岛素利拉鲁肽注射液上市注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2671576276","media":"中金财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671576276?lang=zh_cn&edition=full","pubTime":"2026-09-30 15:07","pubTimestamp":1790752022,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，联邦制药涨超3%，截至发稿，涨3.53%，报7.925港元，成交额2554.06万港元。　　消息面上，近日，联邦制药发布公告，公司全资附属公司珠海联邦生物医药有限公司自主研发的德谷胰岛素利拉鲁肽注射液获得中国国家药品监督管理局上市注册申请受理。公司为国内首家提交德谷胰岛素利拉鲁肽生物类似药上市注册申请的企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260930/32385297.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK4585","03933","BK1191","BK4588","KCAI","VXUS","IE00B3M56506.USD","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670352419","title":"智通港股早知道 | 监管明确险资投资港股通ETF口径 海光芯正(01191)南向持股占比升至4.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2670352419","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670352419?lang=zh_cn&edition=full","pubTime":"2026-09-25 07:52","pubTimestamp":1790293960,"startTime":"0","endTime":"0","summary":"预计本公司将于2026年12月31日前与相关方订立合伙协议及附属协议。 海光芯正：下半年1.6T光模块开始出货 南向持股占比升至4.2%海光芯正在9月9日至11日举行的第27届中国国际光电博览会上，展出全栈自研硅光1.6T光模块和6.4T NPO。此外，南向资金近期持续加仓，海光芯正已于今年9月7日起纳入港股通。截至目前，南向资金持有海光芯正384.44万股，占公司已发行普通股的4.19%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500833.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03692","FDN","FLHK","LU0211977185.USD","BK1521","LU1008478684.HKD","LU1046422090.SGD","LU1960683339.HKD","LU2097828631.EUR","LU1226287529.USD","03933","BK4550","01093","IE00B3M56506.USD","LU1206782309.USD","BK1205","IE00B5MMRT66.SGD","LU1226288170.HKD","SG9999003461.SGD","BK1170","BK1589","02628","LU0315179316.USD","00659","BK1537","KCAI","LU0067412154.USD","LU0326950275.SGD","IE00B031HY20.USD","BK1550","IE00B543WZ88.USD","LU1152091168.USD","LU1226287792.SGD","LU0320764599.SGD","LU1226287875.USD","LU0173614495.USD","01191","LU0307460666.USD","VXUS","LU0287142896.SGD","LU2097828714.EUR","BK1230","KURE","01133","LU0140636845.USD","LU0708995583.HKD","LU1152091754.HKD","IE0032431581.USD","SG9999012710.SGD","LU0871576103.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669491542","title":"联邦制药(03933)收取诺和关于UBT251独家许午可协议的第二次里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2669491542","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669491542?lang=zh_cn&edition=full","pubTime":"2026-09-24 23:01","pubTimestamp":1790262082,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联邦制药(03933)发布公告，于2026年9月23日，联邦生物科技已收取诺和支付的UBT251注射液2型糖尿病适应症全球I期临床里程碑付款900万美元(扣除丹麦预缴税后)。根据独家许可协议并受其条款和条件约束，联邦生物科技有资格收取最高18亿美元的潜在里程碑付款，视乎达成若干开发和销售里程碑而定，以及可收取基于该地区的年度净销售额计算的分层销售提成。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500820.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"联邦制药(03933)收取诺和关于UBT251独家许午可协议的第二次里程碑付款","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","03933","IE00B3M56506.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171048187","title":"联邦制药（03933）获诺和诺德支付UBT251全球II期里程碑款900万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1171048187","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171048187?lang=zh_cn&edition=full","pubTime":"2026-09-24 23:00","pubTimestamp":1790262047,"startTime":"0","endTime":"0","summary":"联邦制药国际控股有限公司（03933）9月24日公告称，其全资附属公司联邦生物科技已于2026年9月23日收到Novo Nordisk A/S（诺和诺德）就UBT251注射液治疗2型糖尿病适应症全球Ⅱ期临床试验达成的里程碑付款900万美元（税后）。\\n\\n该笔款项为双方于2025年3月24日签订之UBT251独家许可协议项下的第二次里程碑付款。根据该协议，联邦生物科技最多可获里程碑款合计18亿美元，并有权按相关地区年度净销售额收取分层销售提成。\\n\\nUBT251是一种同时靶向GLP-1受体、GIP受体及胰高血糖素受体的三重激动剂，用于治疗肥胖、2型糖尿病及其他相关疾病。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669495958","title":"联邦制药中期收入降18%，归母净利降81.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669495958","media":"财闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669495958?lang=zh_cn&edition=full","pubTime":"2026-09-24 20:41","pubTimestamp":1790253660,"startTime":"0","endTime":"0","summary":"9月24日，联邦制药(03933.HK)公布截至2026年6月30日止六个月未经审计中期业绩，收入人民币61.66亿元，同比下降18.0%；本公司拥有人应占本期溢利人民币3.48亿元，同比下降81.6%。未计利息、税项、折旧及摊销前溢利为人民币9.21亿元，同比下降66.5%；除税前溢利为人民币4.65亿元，同比下降80.8%。每股基本盈利为人民币17.62分，同比下降83.1%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-24/doc-inisxtav8248894.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00B3M56506.USD","BK1191","03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669246732","title":"联邦制药(03933)：德谷胰岛素利拉鲁肽注射液上市注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2669246732","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669246732?lang=zh_cn&edition=full","pubTime":"2026-09-24 19:27","pubTimestamp":1790249237,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联邦制药 发布公告，公司全资附属公司珠海联邦生物医药有限公司自主研发的德谷胰岛素利拉鲁肽注射液获得中国国家药品监督管理局上市注册申请受理，受理号为CXSS2600154。公司为国内首家提交德谷胰岛素利拉鲁肽生物类似药上市注册申请的企业。德谷胰岛素利拉鲁肽注射液是一款长效复方降糖制剂，由基础胰岛素德谷胰岛素和人胰高血糖素样肽-1类似物利拉鲁肽组成。本次上市注册申请是公司在糖尿病治疗领域又一重要成果。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500674.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B3M56506.USD","BK1191","IPOS","03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110136157","title":"联邦制药（03933）德谷胰岛素利拉鲁肽注射液上市注册申请获中国药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1110136157","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110136157?lang=zh_cn&edition=full","pubTime":"2026-09-24 19:25","pubTimestamp":1790249131,"startTime":"0","endTime":"0","summary":"2026年9月24日，联邦制药国际控股有限公司发布公告称，其全资子公司珠海联邦生物医药有限公司自主研发的德谷胰岛素利拉鲁肽注射液已获中国国家药品监督管理局受理上市注册申请，受理号为CXSS2600154。该公司成为国内首家提交该生物类似药上市注册申请的企业。\\n\\n德谷胰岛素利拉鲁肽注射液是一款长效复方降糖制剂，由基础胰岛素德谷胰岛素与GLP-1类似物利拉鲁肽组合而成。\\n\\n公司表示，此次注册申请是其在糖尿病治疗领域取得的又一重要进展。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667605723","title":"【券商聚焦】国联民生维持联邦制药（03933）推荐评级 指业绩环比改善显著","url":"https://stock-news.laohu8.com/highlight/detail?id=2667605723","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667605723?lang=zh_cn&edition=full","pubTime":"2026-09-16 16:06","pubTimestamp":1789546009,"startTime":"0","endTime":"0","summary":"金吾财讯 | 国联民生证券发布研报指，联邦制药 2026年上半年实现收入61.66亿元人民币（下同），同比下降18.0%；归母净利润3.48亿元，同比下降81.6%。报告称，许可收入上年同期基数高。随着中间体/原料药价格企稳复苏，公司整体业绩环比改善显著。投资建议方面，报告预计2026-2028年公司营业收入分别为124/132/143亿元人民币，同比增长-6.5%/6.9%/8.6%；归母净利润分别为7.6/10.3/11.7亿元人民币，同比增长-63.6%/35.4%/13.8%。当前股价对应PE分别为18X/13X/12X，维持“推荐”评级。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991741","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","03933","601456","01456"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666831355","title":"瑞银：中国制药股上半年业绩好坏参半 首选先声药业(02096)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666831355","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666831355?lang=zh_cn&edition=full","pubTime":"2026-09-09 15:43","pubTimestamp":1788939780,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研报称，中国制药股上半年业绩好坏参半，在九家评级的制药公司中，有五家业绩好过市场预期，分别为翰森制药、先声药业、中国生物制药、石药集团及科伦药业，联邦制药表现大致符合预期，而三生制药及华东医药表现则逊预期，全数给予“买入”评级。瑞银列先声药业行业首选股，指出先声药业是唯一上调2026年指引的公司，经调整纯利增长目标由30%上调至45%，收入增长维持30%，给予目标价16.6港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493826.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1515","BK1589","03692","01530","IE00BZ08YR35.GBP","HK0000165453.HKD","IE00BZ08YT58.USD","03933","BK1161","IE00B3M56506.USD","BK1521","BK1593","02096","BK1574","IE00BZ08YS42.EUR","01477","01177","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665234873","title":"【券商聚焦】华泰维持联邦制药（03933）买入评级 看好代谢管线及动保业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2665234873","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665234873?lang=zh_cn&edition=full","pubTime":"2026-09-08 16:03","pubTimestamp":1788854597,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华泰发布研报指，联邦制药 1H26实现收入61.7亿元，归母净利润3.48亿元，符合此前盈利预告。收入下滑主因授权费用同比减少及中间体业务销售下滑；利润下滑幅度更大主因6APA价格虽环比提升但仍低于1H25同期水平。展望26年，华泰看好公司维持6-8亿元利润预期，维持“买入”评级，目标价12.61港元。华泰看好UBT251在26年为公司贡献2500万美元里程碑，27年贡献7000万至1.3亿美元里程碑收入。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991036","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191775486","title":"联邦制药(03933)长效三靶点激动剂UBT251在华III期临床完成首例给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1191775486","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191775486?lang=zh_cn&edition=full","pubTime":"2026-09-07 20:46","pubTimestamp":1788785175,"startTime":"0","endTime":"0","summary":"2026年9月7日，联邦制药国际控股有限公司公告称，其全资附属公司联邦生物科技有限公司自主研发的1类创新药UBT251注射液，已在中国针对2型糖尿病的III期临床试验完成首例受试者给药。此次III期项目分为“UNIGUIDE-1”和“UNIGUIDE-2”两项独立研究。据公告，联邦制药是中国首家、全球第二家以化学合成多肽法制备长效GLP-1R/GIPR/GCGR三靶点激动剂并获批临床的企业。此前，联邦生物科技及联邦制药已于2025年3月与Novo Nordisk A/S签署UBT251的独家许可协议。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665314872","title":"联邦制药(03933)：UBT251注射液完成中国2型糖尿病III期临床研究首例试验参与者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2665314872","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665314872?lang=zh_cn&edition=full","pubTime":"2026-09-07 20:45","pubTimestamp":1788785154,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联邦制药 发布公告，公司全资附属公司联邦生物科技有限公司自主研发的 1 类创新药 UBT251 注射液已完成中国 2 型糖尿病 III 期临床研究首例试验参与者给药。本研究将分别进行“UNIGUIDE-1”及“UNIGUIDE-2”两项研究。UNIGUIDE-1 采用随机、双盲、平行、安慰剂对照的试验设计，计划纳入 360 例成人 2 型糖尿病试验参与者，旨在评估 UBT251 注射液在单纯饮食运动干预后血糖控制不佳的 2 型糖尿病试验参与者中的有效性和安全性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493029.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B3M56506.USD","BK1191","03933"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665318052","title":"瑞银：下调联邦制药(03933)目标价至12.8港元 维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2665318052","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665318052?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:04","pubTimestamp":1788771882,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研报称，联邦制药上半年收入同比下降18%至62亿元人民币，仍高于该行及市场预期，受动物保健及授权收入支持;纯利同比下降82%，大致符合初步业绩及该行预期。该行将联邦制药目标价由15港元下调至12.8港元，维持“买入”评级。研发开支同比下降12%至4.39亿元人民币，销售及行政开支则同比增长1.7%至11亿元人民币。人用制剂产品则轻微下降2%至19亿元人民币。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492799.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03933","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665394525","title":"大行评级丨瑞银：下调联邦制药目标价至12.8港元，维持“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2665394525","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665394525?lang=zh_cn&edition=full","pubTime":"2026-09-07 14:17","pubTimestamp":1788761822,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["03933","BK1191","IE00B3M56506.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665398249","title":"【券商聚焦】中信建投：上半年收入与利润双增，医药行业步入新发展周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2665398249","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665398249?lang=zh_cn&edition=full","pubTime":"2026-09-07 09:04","pubTimestamp":1788743053,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，2026年上半年医药行业整体收入与扣非净利润实现双增长，创新药、CXO、制药装备及科学试剂等板块积极复苏，行业步入新发展周期。创新药收入+58.68%，扭亏为盈，出海总金额超900亿美元，全年有望超越2025年水平，国际化持续兑现；CXO收入+25.2%，扣非净利润+66.5%，订单旺盛，上行周期确立。随着集采出清、创新放量、出海落地及上游国产化提升，行业有望开启高质量发展周期，龙头将持续受益。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1990791","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","LU1770034418.SGD","KCE","IE00BPRC5H50.USD","BK1574","02367","LU0417516902.SGD","02228","01099","01530","BK1100","LU2778985437.USD","KURE","LU1720050803.USD","BK1585","09926","02268","LU0348827113.USD","LU1115378108.SGD","03933","06160","BK1191","09688","LU0828237510.HKD","LU2488822045.USD","LU0640798160.USD","01789","BK1197","BK1161","BK1588","LU2399975544.HKD","LU2476274720.SGD","06821","SG9999004311.SGD","601066","LU2328871848.SGD","LU2476274308.USD","BK1515","IE00B3M56506.USD","02196","BK1593","BK1207","LU1969619763.USD","LU0588546209.SGD","LU0348825331.USD","BK1141","BK1583","BK1500","IE00B5MMRT66.SGD","LU0228659784.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664336457","title":"联邦制药(03933)：UBT251注射液完成中国超重/肥胖III期临床研究首例试验参与者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2664336457","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664336457?lang=zh_cn&edition=full","pubTime":"2026-09-04 18:55","pubTimestamp":1788519354,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联邦制药(03933)发布公告，公司全资附属公司联邦生物科技(珠海横琴)有限公司(联邦生物科技)自主研发的1类创新药UBT251注射液已完成中国超重/ 肥胖III期临床研究首例试验参与者给药。本研究采用随机、双盲、平行、安慰剂对照的试验设计，计划纳入600例肥胖(BMI≥28.0 kg/m2)或伴有至少一种体重相关合并症的超重(24.0 kg/m2≤BMI<28.0 kg/m2)试验参与者，旨在评估UBT251注射液在超重/肥胖试验参与者中有效性和安全性。本研究的主要评价终点为给药52周试验参与者体重较基线变化百分比及体重较基线降低≥5%的试验参与者比例。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492214.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B3M56506.USD","BK1191","03933"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tul.com.cn","stockEarnings":[{"period":"1week","weight":-0.0605},{"period":"1month","weight":-0.1387},{"period":"3month","weight":-0.2486},{"period":"6month","weight":-0.2847},{"period":"1year","weight":-0.4597},{"period":"ytd","weight":-0.3921}],"compareEarnings":[{"period":"1week","weight":-0.0452},{"period":"1month","weight":-0.0701},{"period":"3month","weight":-0.0749},{"period":"6month","weight":-0.111},{"period":"1year","weight":-0.1107},{"period":"ytd","weight":-0.099}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"联邦制药国际控股有限公司是一家主要从事制药业务的投资控股公司。该公司通过三个分部运营业务。制剂产品分部主要制造及销售胰岛素系列产品、抗生素产品、眼科产品、兽药产品及空心胶囊等产品。原料药分部主要销售阿莫西林产品。中间体产品分部主要销售6-氨基青霉烷酸产品及青霉素G钾产品。","yearOnYearQuotes":[{"month":1,"riseRate":0.368421,"avgChangeRate":-0.033072},{"month":2,"riseRate":0.736842,"avgChangeRate":0.075941},{"month":3,"riseRate":0.631579,"avgChangeRate":0.024557},{"month":4,"riseRate":0.578947,"avgChangeRate":0.075619},{"month":5,"riseRate":0.631579,"avgChangeRate":0.035298},{"month":6,"riseRate":0.263158,"avgChangeRate":-0.013942},{"month":7,"riseRate":0.55,"avgChangeRate":0.015909},{"month":8,"riseRate":0.45,"avgChangeRate":0.020395},{"month":9,"riseRate":0.4,"avgChangeRate":-0.008264},{"month":10,"riseRate":0.6,"avgChangeRate":-0.008012},{"month":11,"riseRate":0.473684,"avgChangeRate":-0.023224},{"month":12,"riseRate":0.421053,"avgChangeRate":0.011203}],"exchange":"SEHK","name":"联邦制药","nameEN":"UNITED LAB"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"联邦制药(03933)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供联邦制药(03933)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"联邦制药,03933,联邦制药股票,联邦制药股票老虎,联邦制药股票老虎国际,联邦制药行情,联邦制药股票行情,联邦制药股价,联邦制药股市,联邦制药股票价格,联邦制药股票交易,联邦制药股票购买,联邦制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"联邦制药(03933)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供联邦制药(03933)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}